Repatha Reps be warned

Discussion in 'Amgen' started by anonymous, Jan 29, 2020 at 5:58 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I’m leaving soon so I don’t care. If you are selling Repatha there will be a Huge lay-off soon. Look for new Job now. Right now! You have been warned!!!!
     

  2. anonymous

    anonymous Guest

    This is BS, the Frenchies have waved the white flag (no surprise) and inclisiran is probably a year away. Things may change when inclisiran hits the.market but for now it’s all hands on deck and full steam ahead.
     
  3. anonymous

    anonymous Guest

    You've got pharm arep tunnel vision. Praluent is not one of the major determining factors for a Repatha sales force layoff. Praluent Isn't, even, the biggest competitor for Repatha. US Sales on the last earnings call were flat, while Europe was growing. Plus, there are some products that are in Phase 3 studies that have a significant lowering effect on LDL-C and TC, and these products, initial, indications are for a different disease state.

    Repatha sales need to increase quickly, or, when we perform the organizational stress test, there will be another reduction in Repatha headcount.
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    Is the San Antonio CV position available because of an expansion or did someone leave?
     
  6. anonymous

    anonymous Guest

    #BIOHAVENSTRONG

    WE COMIN!
     
  7. anonymous

    anonymous Guest

    Ahh, I knew it was the finance paper-pusher rookie. He/she likes to say "we", as if there is any personal involvement.
     
  8. anonymous

    anonymous Guest

    what would the organization need to see? I see your post is from January. Q4 was +26%, 2019 YOY +20%. $ sales +15% despite a 60% list price reduction. Q1 2020 setting up to be a strong Qtr. it’s headed to be a billion dollar brand with little to no discounts off list price. May not get there with COVID19 interrupting the market....but 2022 for sure.

    so they can reduce headcount but with a HF med on the horizon Red division has to be right sized for that as well.
    As for ISS, significant growth occurring there as well. Maybe they adjust the weighting but a reduction would affect headcount for Aimovig. There is a contract in place with Novartis where we need to deliver x amount of calls for Aimovig. But as it stands now....double digit growth...by dollars and units. Repatha has struggled but is finally hitting its stride after getting outcomes, reduced price, better coverage, and easier to get.
    these changes are working. Record high in volume last week.

    Other lipid drugs? Like the one by Esperion with a whopping 18% reduction in LDL-C, no outcomes, and safety concerns?
     
  9. anonymous

    anonymous Guest

    i like seeing this emo 'tard losing his sh*t
     
  10. anonymous

    anonymous Guest

    Ahh I made his blood vessels pop. Raaaage !
     
  11. anonymous

    anonymous Guest

    Nothing is more fun than seeing the paper pusher having a ragefest
     
  12. anonymous

    anonymous Guest

    Record high volume in last month due to not having g a competitor in PCSK9 market anymore.
     
  13. anonymous

    anonymous Guest

    Also not even close to projections when it came out in 2015. Plus HF drug will not save the division.
     
  14. anonymous

    anonymous Guest

    Also a high for # of writers as well. Neglected to mention that. No doubt not near projections....happens when you over price it to begin with. But the trend is favorable finally.
     
  15. anonymous

    anonymous Guest

    furthermore....volume for Praluent is flat....it’s still on the market...just not being promoted. So more new writers...market is growing with Repatha winning new starts. It’s all there in the data if you look...or are you a former employee talking shit?
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    someone left
     
  18. anonymous

    anonymous Guest

    No, I'm not an ex-employee. I'm currently with Amgen but I still think we are rep heavy. When you say we need the headcount.... WTH are those people going to do all day every day??? Check boxes?? You've GOT to know that's what's happening in a big portion of the US. Access is getting worse and worse everywhere. I'm in a territory in the Southeastern part of the US and our territory was already shut down pretty bad to reps before COVID19. Now it's going to be even worse if at all. I've got a pretty decent size territory but definitely don't need a counterpart. It's ridiculous how much we trip over each other not to mention we have a hospital rep too now? I hear you... Repatha is a great drug with a lot more potential but we're still rep-heavy. I try to keep my head down and hope Amgen continues to pay us twice as much as we actually work. It's not that we don't want to work. We show up and TRY but it's near to impossible to see the docs now. I don't care how good you are.
     
  19. anonymous

    anonymous Guest

    Access varies by geography....yours is a local problem. You are tripping over counterparts? Are you ISS or Red? Shouldn’t you be staying in your lane to avoid that? Or are you 1 of 2 Red reps in same geography? All I’m saying....those issues are local.
     
  20. anonymous

    anonymous Guest

    Repatha barely covers expenses (Within $200k) at the end of the day when you add in all the home office, marketing materials, cars etc. As a stock hold, like all employees, I find it scary that Amgen continues to work with such little cushion. I think something needs to be done to reduce expense or increase revenue.